

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
17 June 2004 (17.06.2004)

PCT

(10) International Publication Number
WO 2004/050585 A1

(51) International Patent Classification⁷: **C07B 53/00**,
41/02, 43/04, C07D 333/16

(21) International Application Number:
PCT/EP2003/050902

(22) International Filing Date:
27 November 2003 (27.11.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2033/02 2 December 2002 (02.12.2002) CH

(71) Applicant (for all designated States except US): SOLVIAS
AG [CH/CH]; Klybeckstrasse 191, CH-4057 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): NAUD, Frédéric,
Maurice [FR/FR]; 8, rue l'Etoile, F-68330 Huningue
(FR). PITTELKOW, Ulrich [DE/DE]; Eichbergstrasse
41, 79618 Rheinfelden (DE).

(74) Agent: MAUÉ, Paul Georg; Solvias AG, Patents, WKL-
402.3.04||Klybeckstrasse 191, CH-4002 Basel (CH).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: CATALYTIC HYDROGENERATION OF CARBON-HETEROATOM DOUBLE BONDS

(57) Abstract: Process for catalytically hydrogenating carbon-heteroatom double bonds, in particular for asymmetrically catalyti-
cally hydrogenating simple ketones, which includes the step of reacting the substrate with hydrogen in the presence of a hydrogenation
catalyst and of a base, characterized in that the hydrogenation catalyst is a 5-coordinate ruthenium complex which in each case has
a monophosphine ligand and a bidentate P-N ligand.



WO 2004/050585 A1

Catalytic hydrogenation of carbon-heteroatom double bonds

The present invention relates to processes for catalytically hydrogenating carbon-heteroatoms double bonds, in particular for asymmetrically catalytically hydrogenating simple ketones, using ruthenium complexes which each have a monophosphine ligand and a bidentate P-N ligand.

The possibilities for reducing carbon-heteroatom double bonds which are relevant from an industrial viewpoint are firstly transfer hydrogenation and secondly hydrogenation with molecular hydrogen. A prerequisite for both processes is the presence of catalysts for activating the particular reducing agent. The hydrogenation activities achievable in transfer hydrogenations are in principle less promising as a result of circumstances relating to the process (need for large amounts of solvent) than in the hydrogenation with molecular hydrogen. Since, however, molecular hydrogen is significantly more difficult to activate than an alcohol, which serves as the reducing agent in the transfer hydrogenation, some catalyst systems for transfer hydrogenation have in recent times become known, but only comparatively few catalyst systems for hydrogenation with hydrogen. In particular, only very few catalyst systems are known hitherto for substrates in the form of simple ketones. Simple ketones are those ketones which have no functional groups, or more precisely no heteroatoms, in the relative vicinity of the carbonyl group, as is the case, for example, in α -keto esters and amides, β -keto esters or amino, hydroxy and phenylthio ketones.

The first example of an efficient catalyst system for the catalytic H_2 hydrogenation of nonfunctionalized ketones is described by R. Noyori and T. Ohkuma in Angew. Chem. Int. Ed. 2001, 40, 40ff. This is a process for asymmetrically hydrogenating simple carbonyl compounds with hydrogen gas under a pressure of up to 50 bar using a homogeneous Ru(II) complex of the $Cl_2Ru(PR_3)_3$ type, in the presence of isopropanol, of a molar excess of a base, and of a nitrogen-containing organic compound in the form of a primary, secondary or tertiary monoamine, or preferably a diamine. The catalytic precursors obtained are 6-coordinate $(Cl)_2Ru(phosphine)_2(N^*N)$ and $(Cl)_2Ru(P^*P)(N^*N)$ complexes. The efficient action of these complexes is attributed to the properties of the amine ligand which, during the catalysis process, functions on the one hand as a hydrogen atom donor for the reduction of the substrate and on the other hand as a hydrogen atom acceptor for the activation of the


molecular hydrogen (R. Noyori and T. Ohkuma in *Angew. Chem. Int. Ed.* 2001, 40, 40ff and R. H. Morris, *Organometallics* 2000, 19, 2655).

The second, later example of a further class of catalysts which enable the hydrogenation of simple ketones is described in WO 02/22526 A2. This describes the preparation of 6-coordinate ruthenium complexes having two bidentate ligands but no amine ligands. The two bidentate ligands are either an N⁺P ligand in combination with a P⁺P ligand, or alternatively two N⁺P ligands.

It is noticeable in the aforementioned examples that, although the complexes have different phosphorus and nitrogen ligands, there are no differences with regard to the coordination sphere on the central ruthenium atom, since the complexes mentioned always have 6-fold coordination. The nature of the ligand sphere around the particular central atom of a complex is known to exert a great influence on the possible activity of the complex.

It has now been found that suitable catalyst precursors for the catalytic hydrogenation of simple ketones with hydrogen are also 5-coordinate ruthenium complexes whose ligands are one monophosphine and one bidentate P⁺N ligand.

The present invention therefore provides a process for hydrogenating a substrate containing a carbon-heteroatom double bond, which includes the step of reacting the substrate with hydrogen in the presence of a hydrogenation catalyst and of a base, characterized in that the hydrogenation catalyst is a transition metal complex of the formula (I)




where

X, Y are each independently a hydrogen atom, halogen atom, C₁₋₈alkoxy or C₁₋₈acyloxy group, or a coordinatively bound organic solvent molecule containing at least one heteroatom having at least one free electron pair, for example in the form of (cyclo)alkyl/aryloxy, -thio or -amino groups, in which case the charge of the resulting cationic complex is balanced by an anion, for example CN⁻, OCN⁻, PF₆⁻ or F₃C-SO₂O⁻,

R₁, R₂, R₃ are each independently an alkyl, alkyloxy, alkylthio, dialkylamino, cycloalkyl, cycloalkyloxy, cycloalkylthio, dicycloalkylamino, aryl, aryloxy, arylthio or diarylamino group, optionally substituted by 1,2 or 3 radicals which are each independently selected from

C₁₋₄alkyl groups and C₁₋₄alkoxy groups, or one of the R₁, R₂, R₃ radicals is as defined above and the remaining 2 radicals which, linked either via an oxygen bridge or directly to the phosphorus atom, form, including the phosphorus atom, a 4- to 8-membered, optionally substituted ring,

P-Z-N is a bidentate ligand which contains an sp²-hybridized nitrogen atom and is of the formula (II)



where

R₄, R₅ are each independently a linear, branched or cyclic C₁₋₈alkyl or C₂₋₈alkenyl group, optionally substituted; C₆₋₁₈aryl, C₃₋₁₈heteroaryl, C₃₋₈cycloalkyl, (C₁₋₆Alkyl)₁₋₃-(Hetero)Aryl, optionally substituted, whereby possible substituents are halogen, organohalogen group, O(C₁₋₆)alkyl, N(C₁₋₈alkyl)₂; or R₄ and R₅ together are a saturated or aromatic ring composed of 5 to 10 atoms including the phosphorus atom,

C_a, C_b are each a part of an aromatic, optionally substituted (hetero)aryl having at least 6 π-electrons,

R₆ is a hydrogen atom, a linear, branched or cyclic C₁₋₁₀alkyl or C₂₋₁₀alkenyl group, optionally substituted, an aromatic ring, optionally substituted, a -OR₆ or -NR₆R₆ radical, where R₆ and R₆ are as defined for R₆,


R₇ is a hydrogen atom, a linear, branched or cyclic C₁₋₁₀alkyl or C₂₋₁₀alkenyl group, or an R₇CO or R₇SO₂ radical where R₇ is a C₁₋₆alkyl or aryl group,

or

R₆ and R₇ together are an unsaturated (hetero)cycle composed of 5 to 10, optionally substituted ring atoms, including the carbon and the nitrogen atom to which R₆ and R₇ are bonded, and optionally including further heteroatoms.

The aforementioned process is suitable for highly selectively hydrogenating ketones to prepare the corresponding optically pure alcohols.

Suitable substrates are ketones of the general formula (S):




When R_a and R_b are different, these are prochiral ketones and the hydrogenation catalyzed by the complexes according to the invention to the corresponding alcohols is enantioselective. The enantiomeric excess is more than 80% (ee), preferably more than 90%, in particular more than 95%.

With regard to the R_a and R_b radicals, there are in principle no restrictions. The radicals are each independently a hydrogen atom, straight-chain or branched alkyl, monocyclic or polycyclic aryl, (hetero)aryl or (hetero)aralkyl groups, and all groups may in turn have further groups such as alkyl, (hetero)aryl or (hetero)aralkyl groups. The carbonyl function to be reduced may also be incorporated into a mono- or polycyclic ring structure. Although a feature of the process according to the invention is that nonfunctionalized ketones in particular can also be hydrogenated, the R_a and R_b radicals may each independently have functional groups. The only restriction for these is that they do not react with the catalyst to destroy it. Possible substituents of the R_a and R_b radicals and in the formula (S) are Hal, OR^x , NR_2^x or R^x , where R^x is H, or a linear, branched or cyclic C_{1-10} alkyl or C_{2-10} alkenyl group.

Preferred substrates are prochiral ketones of the formula (S), where R_a and R_b are each independently a hydrogen atom, a cyclic, linear or branched C_{1-8} alkyl or C_{2-8} alkenyl group, or an monocyclic or polycyclic aryl or heteroaryl group, optionally substituted by linear or branched C_{1-8} alkyl-, C_{1-8} alkoxy groups or halogen atoms.

Examples of substrates of the formula (S) include in particular monocyclic or polycyclic aryl ketones or heteroaryl ketones, optionally substituted by linear or branched C_{1-8} alkyl-, C_{1-8} alkoxy groups or halogen atoms.

The aforementioned process is also suitable for hydrogenating substrates containing a $C=N$ double bond corresponding to the general formula (O):



When R_a and R_b are different, these are prochiral imines and the hydrogenation catalysed by the complexes according to the invention to the corresponding amines is enantioselective. The enantiomeric excess is more than 80% (ee), preferably more than 90%, in particular more than 95%.

With regard to the R_a and R_b radicals, there are in principle no restrictions. The possible R_a and R_b radicals correspond to those specified under the formula (S). R in the formula (O) may be, for example, an H, OR, SR, $P(O)R_2$ radical where R may in each case be a linear or branched C_{1-8} alkyl or alkenyl group, optionally substituted, or an aromatic ring, optionally substituted. Possible substituents of the NR radical are Hal, OR^* , NR_2^* or R^* where R^* is H, or a linear, branched or cyclic C_{1-10} alkyl or alkenyl group.


The process according to the invention for hydrogenating a substrate containing a carbon-heteroatom double bond is characterized in that the hydrogenation catalyst is a transition metal complex of the general formula (I):



In the formula (I), X and Y are preferably each independently a hydrogen atom or a halogen atom, preferably a chlorine atom. Particular preference is given to X and Y each being a chlorine atom.

Monophosphines $P R_1 R_2 R_3$ used with preference in the complexes of the formula (I) according to the invention are those in which the R_1 , R_2 , R_3 radicals are each independently a C_{1-4} alkyl group, C_{5-6} cycloalkyl group, or a phenyl group, optionally substituted by 1,2 or 3 radicals which are each independently selected from C_{1-4} alkyl groups and C_{1-4} alkoxy groups. They are preferably methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, cyclopentyl, cyclohexyl or phenyl, o- or p-tolyl, p-isopropylphenyl or mesityl. Particularly preferred monophosphines are triphenylphosphine, tri- C_{1-4} alkylphosphine, tritolylphosphine or trimesitylphosphine.

The P-Z-N moiety in the complexes of the formula (I) according to the invention is a bidentate ligand which contains one nitrogen atom and is of the formula (II):



In the formula (II), R_4 , R_5 are each independently preferably C_{1-4} alkyl, preferably each independently methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl. R_4 , R_5 are each independently more preferably C_{6-18} aryl, C_{3-18} heteroaryl, C_{3-8} cycloalkyl, $(C_{1-8}Alkyl)_{1-3}$ -(Hetero)Aryl, optionally substituted, whereby possible substituents are halogen, organohalogen group, $O(C_{1-8})$ alkyl,


$N(C_{1-8}alkyl)_2$; or R_4 and R_5 together are a saturated or aromatic ring composed of 5 to 10 atoms including the phosphorus atom.

When R_4 and R_5 together form a saturated or aromatic ring including the phosphorus atom, R_4 and R_5 together are preferable n-butylene, n-pentylene or 2,2'-biphenylene.

In the formula (II), C_a , C_b together form part of an aromatic, optionally substituted (hetero)aryl having 6 or more than 6 π -electrons. The basic aromatic structures may be fused benzene in the form of polycyclic aromatics such as naphthalene, anthracene, phenanthrene or heteroaromatics such as quinoline or isoquinoline, or a cyclopentadienide ion as a ligand of a metallocene. It is preferably a pure 6 π -electron system in the form of in each case optionally substituted benzene, or a 6 π - or 10 π -electron heteroaromatic system.

In the formula (II), R_6 and R_7 are preferably each independently a hydrogen atom, a linear or branched $C_{1-4}alkyl$ group, optionally substituted, or an aromatic ring, optionally substituted, or R_6 and R_7 together with particular preference form an unsaturated heterocycle composed of 5 to 10, optionally substituted ring atoms, including the carbon and the nitrogen atom to which R_6 and R_7 are bonded, and optionally including further heteroatoms.

Preferred ligands of the formula (II) are firstly ligands of the general formula (IIIa),



where

$n = 1$ or 2 , preferably 1 ,

m , depending on M , is the number of free coordination sites on the central atom M ,

$M = Cr, Mo, Fe, Ru, Os, Mn$ or Re , preferably Re ,

$X = O, S$ or N , preferably O ,

L are each independently mono- or polydentate ligands to fill the free coordination sites on the central atom M , such as $P(C_{6-18}aryl)_3$, $P(C_{6-18}alkyl)_3$, $H_2NCH_2CH_2NH_2$,


$(C_{6-18}aryl)_2PCH_2CH_2P(C_{6-18}aryl)_2$ or preferably CO ,

R_4, R_5 are each radicals corresponding to the definition given under formula (II),

R_{11} is a C_{2-8} alkoxyalkyl, C_{7-19} aralkyl, C_{3-18} heteroaryl, C_{4-19} heteroaralkyl, $(C_{1-8}$ alkyl) $_{1-3}$ - C_{6-18} (hetero)aryl, $(C_{1-8}$ alkyl) $_{1-3}$ - C_{6-18} cycloalkyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkyl- C_{1-8} alkyl radical, or preferably a C_{1-8} alkyl, C_{6-18} aryl radical, and the radicals mentioned may be substituted by one or more heteroatoms such as Hal, Si, N, O, P, S, or the radicals may have one or more heteroatoms such as Si, N, O, P, S in their carbon framework,

$R_{8,9,10}$ are each independently a C_{1-8} alkyl, C_{2-8} alkoxyalkyl, C_{6-18} aryl, C_{7-19} aralkyl, C_{3-18} heteroaryl, C_{4-19} heteroaralkyl, $(C_{1-8}$ alkyl) $_{1-3}$ - C_{6-18} (hetero)aryl, C_{3-8} cycloalkyl, $(C_{1-8}$ alkyl) $_{1-3}$ - C_{6-18} cycloalkyl, C_{3-8} cycloalkyl- C_{1-8} alkyl radical, or preferably H, and the radicals mentioned may be substituted by one or more heteroatoms such as Hal, Si, N, O, P, S, or the radicals may have one or more heteroatoms such as Si, N, O, P, S in their carbon framework.

Preferred ligands of the formula (II) are also ligands of the formula (IIIb)



where

$n = 1$ or 2 , preferably 1 ,

$M = \text{Fe, Ru, Os}$, preferably Fe ,

$X = \text{O, S or N}$, preferably O ,


R_4, R_5 are each radicals corresponding to the definition given under formula (II),

R_{11} is a C_{2-8} alkoxyalkyl, C_{7-19} aralkyl, C_{3-18} heteroaryl, C_{4-19} heteroaralkyl, $(C_{1-8}$ alkyl) $_{1-3}$ - C_{6-18} (hetero)aryl, $(C_{1-8}$ alkyl) $_{1-3}$ - C_{6-18} cycloalkyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkyl- C_{1-8} alkyl radical, or preferably C_{1-8} alkyl, C_{6-18} aryl radical, in particular *i*-propyl, and the radicals mentioned may be substituted by one or more heteroatoms such as Hal, Si, N, O, P, S, or the radicals may have one or more heteroatoms such as Si, N, O, P, S in their carbon framework,

$R_{8,9,10}$ are each independently a C_{1-8} alkyl, C_{2-8} alkoxyalkyl, C_{6-18} aryl, C_{7-19} aralkyl, C_{3-18} heteroaryl, C_{4-19} heteroaralkyl, $(C_{1-8}$ alkyl) $_{1-3}$ - C_{6-18} (hetero)aryl, C_{3-8} cycloalkyl, $(C_{1-8}$ alkyl) $_{1-3}$ - C_{6-18} cycloalkyl, C_{3-8} cycloalkyl- C_{1-8} alkyl radical, or preferably H, and the radicals mentioned may be substituted by one or more heteroatoms such as Hal, Si, N, O, P, S, or

the radicals may have one or more heteroatoms such as Si, N, O, P, S in their carbon framework, and the lower cyclopentadienide ligand in the formula may, with respect to the abovementioned possible substitution pattern for the upper cyclopentadienide ligand, be correspondingly substituted with regard to the possible $PR_{4,5}$ and $R_{8,9,10}$ radicals.

As already mentioned, C_a , C_b in the formula (II) together form part of an aromatic, optionally substituted (hetero)aryl having 6 or more than 6 π -electrons, which is preferably a pure 6 π -electron system in the form of in each case optionally substituted benzene, or is a 6 π - or 10 π -electron heteroaromatic system. Preferred ligands of the formula (II) are therefore also ligands of the general formulae (IV) and (V):



where

$n = 1$ or 2 , preferably 1 ,

$X = O, S$ or N , preferably O ,

R_4, R_5 are each radicals corresponding to the definition given under formula (II),


R_{11} is a C_{2-8} alkoxyalkyl, C_{7-19} aralkyl, C_{3-18} heteroaryl, C_{4-19} heteroaralkyl,

$(C_{1-8}alkyl)_{1-3}$ - C_{6-18} (hetero)aryl, $(C_{1-8}alkyl)_{1-3}$ - C_{6-18} cycloalkyl, C_{3-8} cycloalkyl,

C_{3-8} cycloalkyl- $C_{1-8}alkyl$ radical, or preferably $C_{1-8}alkyl$, $C_{6-18}aryl$ radical, in particular *i*-propyl, and the radicals mentioned may be substituted by one or more heteroatoms such as Hal, Si, N, O, P, S, or the radicals may have one or more heteroatoms such as Si, N, O, P, S in their carbon framework,

R_{12}, R_{13} are each independently a $C_{1-8}alkyl$, $C_{1-4}alkoxy$ radical, or preferably H, or are together a fused cycloalkyl or aryl ring.


Preferred ligands of the formula (II) are also ligands of the general formula (V)




where

n, X, R₄, R₅ and R₁₁ are each as defined under formula (IV), and R₁₄ and R₁₅ together are a 6 π - or 10 π -electron heteroaromatic system, optionally substituted by linear or branched C₁₋₈alkyl radicals, and possible heteroatoms are N, O, or S.


Particularly preferred ligands of the general formula (IIIb) correspond to the following ligands A to G:



A particularly preferred ligand of the general formula (IV) corresponds to the formula J:



Particularly preferred ligands of the general formula (V) correspond to the formulae H, I and K:



Linear or branched C_{1-8} alkyls are to be regarded as being methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl or octyl, including all of their structural isomers.

C_{2-8} Alkoxyalkyls mean radicals in which the alkyl chain is interrupted by at least one oxygen function, although two oxygen atoms may not be joined together. The number of carbon atoms indicates the total number of carbon atoms present in the radical. All structural isomers are included.

C_{3-8} Cycloalkyl radical refers to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl radicals, etc. Cycloalkyl radicals substituted by heteroatoms are preferably, for example, 1-, 2-, 3-, 4-piperidyl, 1-, 2-, 3-pyrrolidinyl, 2-, 3-tetrahydrofuryl, 2-, 3-, 4-morpholinyl.

A C_{3-8} cycloalkyl- C_{1-8} alkyl radical denotes a cycloalkyl radical as illustrated above which is linked to the molecule via an alkyl radical as specified above.

A C_{6-18} aryl radical refers to an aromatic radical having 6 to 18 carbon atoms. These include in particular compounds such as phenyl, naphthyl, anthryl, phenanthryl, biphenyl radicals.

A C_{7-19} aralkyl radical is a C_{6-18} aryl radical linked to the molecule via a C_{1-8} alkyl radical.

In the context of the invention, a C_{3-18} heteroaryl radical denotes a five-, six- or seven-membered aromatic ring system composed of 3 to 18 carbon atoms which has heteroatoms in the ring, for example nitrogen, oxygen or sulphur. Such heteroaromatics are regarded as being in particular radicals such as 1-, 2-, 3-furyl, 1-, 2-, 3-pyrrolyl, 1-, 2-, 3-thienyl, 2-, 3-, 4-pyridyl, 2-, 3-, 4-, 5-, 6-, 7-indolyl, 3-, 4-, 5-pyrazolyl, 2-, 4-, 5-imidazolyl, acridinyl, quinolinyl, phenanthridinyl, 2-, 4-, 5-, 6-pyrimidinyl.

A C₄₋₁₉heteroaralkyl refers to a heteroaromatic system as defined above corresponding to the C₇₋₁₉aralkyl radical.

Hal is fluorine, chlorine, bromine, iodine, preferably chlorine. Organohalogen compounds is the collective term used for compounds containing, in addition to carbon, elements of the halogen group, including fluorine, chlorine, bromine and iodine. An example is the CF₃ group.

The specific bidentate P-Z-N ligands of the general formula (II) and their preparation are known in principle from the literature. Some references are cited in the experimental section. The transition metal complexes of the general formula (I) may if desired be prepared "in situ" in the reaction mixture which contains the substrate to be hydrogenated, or may initially be isolated before a hydrogenation. The preparative process of the complexes is in principle the same. When preparing the complexes, the P-Z-N ligand is in principle introduced stoichiometrically.

The transition metal complexes of the general formula (I) may advantageously be used to hydrogenate simple ketones in particular. Indeed even simple ketones which do not contain a coordinating heteroatom nearby the carbonyl group can be hydrogenated with high activity and enantioselectivity. In the light of the high activity of the catalyst, reduction of non prochiral ketone to make achiral alcohol can be also of practical interest for cost efficient synthesis of secondary alcohol.

The hydrogenation is typically effected in compositions comprising a complex of the formula (I), the substrate, a base and optionally a solvent. Hydrogen is then injected to this composition under the desired pressure and at the desired temperature. The hydrogenation conditions to be selected follow in principle from the customary conditions and essential process parameters such as pressure, temperature, concentration of substrate and catalyst, solvent, bases, which are known from the prior art. The process conditions outlined below have only exemplary character.

The concentration range of the complexes based on the substrate may vary widely. In general, based on the substrate, between 0.1 and 50 000 ppm are used. This corresponds to a substrate/complex ratio (S/C) of 10⁷ to 20.

The bases used may be any inorganic or organic bases customarily used in hydrogenation. Mention is made only of alkali metal and alkaline earth metal hydroxides, alkoxides and carbonates, and quaternary ammonium salts. Preference is given to using KOH, KOMe,

KOiPr, KOtBu, LiOH, LiOMe, LiOiPr, NaOH, NaOMe or NaOiPr. The bases may be used in solid form or dissolved in alcohol or preferably in water, for example KOtBu/tBuOH (1 molar) or NaOH/H₂O (1 molar). In addition, the bases used may be used within a large concentration range. In molar equivalents of base, expressed relative to the metal complex (B/M), the ratio may be about 0.5 to 50 000, preferably 2 to 10 000.

The process according to the invention can be carried out without or in the presence of an inert solvent. Suitable solvents are, for example, aliphatic, cycloaliphatic and aromatic hydrocarbons (pentane, hexane, petroleum ether, cyclohexane, methylcyclohexane, benzene, toluene, xylene), aliphatic halohydrocarbons (methylene chloride, chloroform, di- and tetrachloroethane), nitriles (acetonitrile, propionitrile, benzonitrile), ethers (diethyl ether, dibutyl ether, t-butyl methyl ether, ethylene glycol dimethyl ether, ethylene glycol diethyl ether, diethylene glycol dimethyl ether, tetrahydrofuran or dioxane), ketones (acetone, methyl isobutyl ketone), carboxylic esters and lactones (ethyl or methyl acetate, valerolactone), N-substituted lactams (N-methylpymolidone), carboxamides (dimethylacetamide, dimethylformamide), acyclic ureas (tetramethylurea) or cyclic ureas (dimethylimidazolidinone), and sulfoxides and sulphones (dimethyl sulfoxide, dimethyl sulphone, tetramethylene sulfoxide, tetramethylene sulphone) and alcohols (methanol, ethanol, propanol, butanol, ethylene glycol monoethyl ether, diethylene glycol monomethyl ether) and water. The solvents may be used alone or in a mixture of at least two solvents. Preference is given to using toluene.


The hydrogenation process according to the invention may be carried out at typical pressures of 10×10^3 to 10×10^5 Pa (1 to 100 bar). Advantageously, 20×10^4 to 85×10^4 (20 to 85 bar), in particular 80×10^4 Pa (80 bar), are used.

The hydrogenation reactions are typically carried out at standard room temperature, i.e. between about 20°C and 35°C. However, depending mainly on the solvents used, or more specifically the solubility behaviour of the reactants used, the selected temperature may also be between about 0°C and 100°C.


The nonlimiting examples which follow illustrate the invention in detail:

Examples:


The substrates used were:




1




2




3




4



5




6



7

Ligands used were:



The ligands A to D were prepared in accordance with reference (1). The ligands E to G were prepared in accordance with the experimental section which follows. The ligands H, I and K were prepared in accordance with reference (2). The ligand J is commercially available from Strem.

The catalyst $[\text{RuCl}_2(\text{PPh}_3)]$ (A) is prepared in accordance with reference (3).

(1) S. Uemura et al., *J. Organometallic Chem.*, 1999, 572, 163

(2) L. Tietze et al., *Synlett* 2002, 12, 2083.

(3) S. Uemura, M. Hidai et al., *Organometallics* 1999, 18, 2291;

Preparation of ligands E, F and G:

Ligand E:

A 250 ml 3-necked flask is charged with ferrocene-oxazoline precursor (2.0 g, 6.8 mmol), prepared in accordance with the abovementioned reference (3), TMEDA (1.2 ml, 8.2 mmol) and 70 ml of diethyl ether. The solution is cooled to -70°C and it becomes yellow and cloudy. A syringe is used to slowly (over about 10 min) add $n\text{-BuLi}$ (1.6 M hexane, 5.5 ml, 8.8 mmol), while keeping the temperature of the reaction mixture below -65°C . After the addition, the mixture is stirred at -70°C for 2 hours, the dry ice bath is removed and the reaction solution is stirred at $0\text{--}5^\circ\text{C}$ for a further 15 min. A syringe is now used to slowly (over about 10 min) add 3.5 g of $\text{PCl}(\text{xyllyl})_2$, 12.6 mmol. The now dark orange-coloured solution is stirred at room temperature for about 15 min, and 50 ml of diethyl ether are subsequently added. The reaction is now stopped by adding 30 ml of a saturated NaHCO_3 solution. Extraction is effected 3 times with 50 ml each time of EtOAc, and the combined organic phases are dried over Na_2SO_4 . After removing the solvents on a rotary evaporator, 3.3 g of an orange-brown-coloured oil are obtained. This is purified by column chromatography (240 g of SiO_2 , 4:1 heptane/ethyl acetate) to obtain 1.5 g of a pure orange-coloured crystalline product. Yield: 1.5 g, 46% of theory).

^1H NMR (300.13 MHz, C_6D_6): δ 0.95 (d, 3 H, HCH_3), 1.05 (d, 3 H, HCH_3), 1.65 (m, 1 H, $\text{CH}(\text{CH}_3)_2$), 2.1 (s, 1 H, Ar- CH_3), 2.2 (s, 1 H, Ar- CH_3), 3.80 (m, 2 H, O- $\text{CH}_2\text{-CH-}$), 3.90 (m, 1 H, O- $\text{CH}_2\text{-CH-}$), 3.95 (m, 1 H, Cp-H), 4.10 (m, 1 H, Cp-H), 4.30 (s, 5 H, Cp), 5.20 (m, 1 H, Cp-H), 6.80 (br. s, 1 H, Ar-H), 6.90 (br. s, 1 H, Ar-H), 7.35 (m, 2 H, Ar-H), 7.60 (m, 2 H, Ar-H).
 $^{31}\text{P}\{^1\text{H}\}$ (121.5 MHz, C_6D_6): δ -16.4.

Ligand F

A 250 ml 3-necked flask is charged with ferrocene-oxazoline precursor (2.0 g, 6.8 mmol), prepared in accordance with the abovementioned reference (3), TMEDA (1.2 ml, 8.2 mmol) and 60 ml of diethyl ether. The solution is cooled to -70°C and it becomes yellow. A syringe

is used to slowly (over about 10 min) add n-BuLi (1.6 M hexane, 5.5 ml, 8.8 mmol), while keeping the temperature of the reaction mixture below -65°C. After the addition, the mixture is stirred at -70°C for 3 hours, the dry ice bath is removed and the reaction solution is stirred at 0-5°C for a further 15 min. A syringe is now used to slowly (over about 10 min) add 1.8 g of $\text{PCl}(\text{p-CF}_3\text{-aryl})_2$, 6 mmol. The now dark orange-coloured solution is stirred at room temperature for about 60 min, and 50 ml of diethyl ether are subsequently added. The reaction is now stopped by adding 30 ml of a saturated NaHCO_3 solution. Extraction is effected 3 times with 50 ml each time of EtOAc, and the combined organic phases are dried over Na_2SO_4 . After removing the solvent on a rotary evaporator, a brown oil is obtained. A small amount of ethyl acetate is added so that the oil just dissolves. Heptane is now added slowly, which leads to the precipitation of an orange-coloured precipitate (1 g) which is removed by means of a frit. After removing the solvents in the filtrate on a rotary evaporator, a brown-coloured oil is obtained. This is purified by column chromatography (120 g of SiO_2 , 4:1 heptane/ethyl acetate) to obtain 1.4 g of a pure orange-coloured crystalline product. Yield: 2.4 g, 65% of theory.

^1H NMR (300.13 MHz, C_6D_6): δ 0.95 (d, 3 H, HCH_3), 1.05 (d, 3 H, HCH_3), 1.65 (m, 1 H, $\text{CH}(\text{CH}_3)_2$), 3.50 (broad s, 1 H, Cp-H), 3.75 (m, 2 H, O- CH_2 -CH-), 3.95 (m, 1 H, O- CH_2 -CH-), 4.10 (1 H, Cp-H), 4.20 (s, 5 H, Cp), 5.10 (broad s, 1 H, Cp-H), 7.20-7.50 (m, aryl-H, 8 H).
 $^{31}\text{P}\{^1\text{H}\}$ (121.5 MHz, CDCl_3): δ -16.9.

Ligand G:

A 250 ml 3-necked flask is charged with ferrocene-oxazoline precursor (2.97 g, 10 mmol), prepared in accordance with the abovementioned reference (3), TMEDA (1.8 ml, 12.0 mmol) and 60 ml of diethyl ether. The solution is cooled to -70°C and it becomes yellow and cloudy. A syringe is used to slowly (over about 10 min) add n-BuLi (1.6 M hexane, 8.6 ml, 13.6 mmol), while keeping the temperature of the reaction mixture below -65°C. After the addition, the mixture is stirred at -70°C for 2 hours, the dry ice bath is removed and the reaction solution is stirred at 0-5°C for a further 15 min. A syringe is now used to slowly (over about 10 min) add 6.0 g of $\text{PCl}(3,5\text{-CF}_3\text{-aryl})_2$, 12.2 mmol. The now dark orange-coloured solution is stirred at room temperature for about 15 min, and 50 ml of diethyl ether are subsequently added. The reaction is now stopped by adding 30 ml of a saturated NaHCO_3 solution. Extraction is effected 3 times with 50 ml each time of Et_2O , and the combined organic phases are dried over Na_2SO_4 . After removing the solvents on a rotary evaporator, 9.0 g of an brown-coloured oil are obtained. This is purified by column chromatography

(380 g of SiO₂, 4:1 heptane/ethyl acetate) to obtain 3.0 g of a dark orange-coloured crystalline product. Yield: 3.0 g, 42% of theory.

¹H NMR (300.13 MHz, CDCl₃): δ 0.85 (d, 3 H, HCH₃), 0.95 (d, 3 H, HCH₃), 1.60 (m, 1 H, CH(CH₃)₂), 3.40 (br. s, 1 H, Cp-H), 3.70 (m, 1 H, O-CH₂-CH-), 3.95 (m, 1 H, O-CH₂-CH-), 4.15 (6 H, Cp-H), 4.40 (m, 1 H, O-CH₂-CH-), 4.95 (m, 1 H, Cp-H), 7.60 (m, 2 H, Ar-H), 7.75 (m, 1 H, Cp-H), 7.90 (m, 3 H, Cp-H). ³¹P{¹H} (121.5 MHz, CDCl₃): δ -15.2.

Procedure for the experiments:

All reactions were carried out using Schlenk technology and under protective gas atmosphere.

General hydrogenation:

After an appropriate pre-treatment, the particular catalyst solution is transferred to the inertized 50 ml mini-autoclave (inject argon and decompress 3 x), and the starting material (substrate) and the base are subsequently added. Afterwards, the autoclave is sealed and hydrogen is injected to the desired pressure. The reaction is started by switching on the magnetic stirrer. When the hydrogenation time has elapsed, the magnetic stirrer is switched off and the autoclave is ventilated. A sample for the GC analysis is taken to determine yield and conversion.

Determination of the conversion and of the ee value:

Conversion and ee value are determined on these substrates in one analysis step.

Column: Beta-Dex 110 (30m); 110°C isothermal; 100 k Pa of H₂ as carrier gas;

Reactant 1 = 5.6 min; E1 = 7.7 min; E2 = 8.1 min.

Reactant 5 = 8.8 min; E1 = 12.5 min; E2 = 13.0 min.

Reactant 7 = 6.2 min; E1 = 8.4 min; E2 = 8.8 min.

Column: Beta-Dex 110 (30m); 110°C isothermal; 120 k Pa of H₂ as carrier gas;

Reactant 4 = 23.4 min; E1 = 25.7 min; E2 = 26.7 min.

Reactant 6 = 7.3 min; E1 = 13.6 min; E2 = 14.3 min.

Column: Beta-Dex 110 (30m); 130°C isothermal; 100 k Pa of H₂ as carrier gas;

Reactant 2 = 5.7 min; E1 = 9.5 min; E2 = 10.9 min.

Reactant 3 = 7.7 min; E1 = 11.1 min; E2 = 11.7 min.

Results

Details of the experiments 1 to 64 with regard to the reactants used, reaction conditions and the results achieved are listed in the following Table 1:

Table 1 (Part 1)(for Part 2 see next page):

Experiment	Ligand	Substrate	P(H ₂)	S/C	Time	Yield	ee
			[bar]		[h]	[%]	[%]
1	A	1	none	200	20	96	89.0
2	A	1	1.1	200	20	98	99.0
3	A	1	80	200	1	99	98.1
4	B	1	80	200	1	99	-98.3
5	C	1	80	200	1	98	95.8
6	D	1	80	200	1	99	98.5
7	E	1	80	200	1	98	97.2
8	F	1	80	200	1	99	95.0
9	G	1	80	200	1	96	92.9
10	H	1	80	200	1	89	96.9
11	I	1	80	200	1	77	93.0
12	J	1	80	200	1	77	86.7
13	K	1	80	200	1	56	96.1
14	A	2	80	200	1	99	94.7
15	B	2	80	200	1	99	-90.4
16	C	2	80	200	1	99	93.6
17	D	2	80	200	1	99	92.9
18	E	2	80	200	1	99	90.2
19	F	2	80	200	1	99	94.3
20	G	2	80	200	1	97	93.2
21	H	2	80	200	1	76	90.7
22	I	2	80	200	1	61	82.3
23	J	2	80	200	1	57	72.6
24	K	2	80	200	1	48	76.8
25	A	3	80	200	1	99	95.8
26	B	3	80	200	1	96	-96.9
27	C	3	80	200	1	98	94.9
28	D	3	80	200	1	97	96.6
29	E	3	80	200	1	98	96.4
30	F	3	80	200	1	98	94.1
31	G	3	80	200	1	98	91.9
32	H	3	80	200	1	80	95.0
33	I	3	80	200	1	72	89.5

Experiment	Ligand	Substrate	P(H ₂)	S/C	Time	Yield	ee
34	J	3	80	200	1	67	36.7
35	K	3	80	200	1	55	89.8
36	A	4	80	200	1	98	95.0
37	B	4	80	200	1	97	-95.3
38	C	4	80	200	1	95	95.6
39	D	4	80	200	1	86	97.5
40	E	4	80	200	1	98	95.7
41	F	4	80	200	1	70	84.4
42	G	4	80	200	1	43	88.4
43	H	4	80	200	1	51	95.3
44	I	4	80	200	1	28	90.7
45	J	4	80	200	1	63	82.4
46	K	4	80	200	1	27	95.4
47	A	5	80	200	1	99	98.4
48	B	5	80	200	1	97	-95.7
49	C	5	80	200	1	100	98.3
50	D	5	80	200	1	80	99.3
51	E	5	80	200	1	98	98.0
52	F	5	80	200	1	94	96.2
53	G	5	80	200	1	80	93.7
54	H	5	80	200	1	56	96.2
55	I	5	80	200	1	45	95.1
56	J	5	80	200	1	48	91.6
57	K	5	80	200	1	14	94.1
58	A	6	80	200	42	86	97.2
59	A	7	80	200	1	10	93.9
60	A	1	80	10 000	1	98	98.5
61	A	1	80	50 000	78	99	99.0
62	A	1	80	10 000	6	98	98.5
63	A	3	20	20 000	1	92	96.2
64	E	3	20	20 000	1	92	95.5
65	E	3	20	20 000	1.5	99	97.5

Experiments 1 and 2: These are carried out under typical transfer hydrogenation conditions. To 10 ml of isopropanol are added: 0.005 mmol of [RuCl₂(PPh₃)₃(A)], 1 mmol of the substrate 1 and 0.025 mmol of *i*PrOK as a base. The reaction is carried out at room temperature under argon in experiment 1 and at a hydrogen pressure of 1.1 bar in experiment 2.

Experiments 3 to 59: The particular catalyst is prepared "in situ" by allowing 0.1 mmol of ligand and 0.1 ml of $[\text{RuCl}_2(\text{PPh}_3)_3]$ in 20 ml of toluene to react for one hour under reflux conditions. 2 ml of the resulting solution are then added to 2 mmol of the substrate which is in a 20 ml flask. 1 ml of a 1 molar aqueous solution of NaOH is then added and the flask is placed in a multiparallel autoclave. Hydrogen is then injected to a pressure of 80 bar for one hour (unless stated otherwise, see table).


Experiments 60 to 62: A Schlenk flask is charged with 0.005 mmol of $[\text{RuCl}_2(\text{PPh}_3)(\text{A})]$, 50 mmol of substrate and 18 ml of toluene in experiment 60, or 250 mmol of substrate and 2 ml of toluene in experiment 61, and 1 ml of a 1 molar aqueous solution of NaOH. The compositions are placed in 50 ml autoclave and subjected to a hydrogen pressure of 80 bar for one hour in experiment 60, and for 78 hours in experiment 61. For reaction 62, the same reaction conditions were used as for 60 except that the reaction was conducted as "neat", namely without addition of toluene.

Experiments 63 to 65: A Schlenk flask is charged with 0.005 mmol of $[\text{RuCl}_2(\text{PPh}_3)_3]$, 0.005 mmol of ligand and 9 ml of toluene and kept under reflux conditions for one hour. 100 mmol of the substrate and 1 ml of a 1 molar aqueous solution of NaOH are then added at room temperature to the catalyst prepared "in situ". The compositions are placed in a 50 ml autoclave and subjected to a hydrogen pressure of 20 bar for one or one and a half hours (see table).

Discussion of the results

The first two comparative experiments which were carried out under the typical conditions of the transfer hydrogenation show that the application of a hydrogen pressure of 1.1 bar has little influence on the activity but enables higher enantioselectivity. This interesting and important result shows that the hydrogenation with hydrogen enables one of the major disadvantages of the transfer hydrogenation to be avoided, i.e. the decrease in the percentage enantioselectivity with increasing time (which approaches the equilibrium). It was also possible to show that for hydrogenations under elevated pressure of 20 to 80 bar, in the presence of an organic solvent such as toluene instead of isopropanol, turnover numbers of up to 50 000 can be achieved. It is also remarkable that a substrate such as isobutyrophenone (substrate 6) which is known to be difficult to hydrogenate can be hydrogenated under comparable conditions with high enantioselectivity (ee = 97.2%).

Hydrogenation of imines (substrate 8):



8

Table 2:

Experiment	Ligand	Substrate	P(H ₂)	S/C	Time	Yield	ee
			[bar]		[h]	[%]	[%]
66	A	8	80	50	16	15	90
67	J	8	80	50	16	14	91

Experiments 66 and 67: The particular catalyst is prepared "in situ" by allowing 0.1 mmol of ligand and 0.1 ml of [RuCl₂(PPh₃)₃] in 20 ml of toluene to react for one hour under reflux conditions. 2 ml of the resulting solution are then added to 2 mmol of the substrate which is in a 20 ml flask. 1 ml of a 1 molar aqueous solution of NaOH is then added and the flask is placed in a multiparallel autoclave. Hydrogen is then injected to a pressure of 80 bar for 16 hours. The results are listed in table 2 above.

Discussion of the results:

It is interesting to note that even with difficult hydrogenation substrates such as imines, the hydrogenation proceeds following analogous conditions to the one described with ketones. Remarkable enantiomeric excesses higher than 90% ee can be achieved.

- 22 -

Claims:

1. Process for hydrogenating a substrate containing a carbon-heteroatom double bond, which includes the step of reacting the substrate with hydrogen in the presence of a hydrogenation catalyst and of a base, characterized in that the hydrogenation catalyst is a transition metal complex of the formula (I)




where

X, Y are each independently a hydrogen atom, halogen atom, C₁₋₈alkoxy or C₁₋₈acyloxy group, or a coordinatively bound organic solvent molecule containing at least one heteroatom having at least one free electron pair, for example in the form of (cyclo)alkyl/aryloxy, -thio or -amino groups, in which case the charge of the resulting cationic complex is balanced by an anion, for example CN⁻, OCN⁻, PF₆⁻ or F₃C-SO₂O⁻,

R₁, R₂, R₃ are each independently an alkyl, alkyloxy, alkylthio, dialkylamino, cycloalkyl, cycloalkyloxy, cycloalkylthio, dicycloalkylamino, aryl, aryloxy, arylthio or diarylamino group, optionally substituted by 1,2 or 3 radicals which are each independently selected from C₁₋₄alkyl groups and C₁₋₄alkoxy groups, or one of the R₁, R₂, R₃ radicals is as defined above and the remaining 2 radicals which, linked either via an oxygen bridge or directly to the phosphorus atom, form, including the phosphorus atom, a 4- to 8-membered, optionally substituted ring,

P-Z-N is a bidentate ligand which contains an sp²-hybridized nitrogen atom and is of the formula (II)



where

R₄, R₅ are each independently a linear, branched or cyclic C₁₋₈alkyl or C₂₋₈alkenyl group, optionally substituted; C₆₋₁₈aryl, C₃₋₁₈heteroaryl, C₃₋₈cycloalkyl, (C₁₋₈Alkyl)₁₋₃-(Hetero)Aryl, optionally substituted, whereby possible substituents are halogen, organohalogen group, O(C₁₋₈)alkyl, N(C₁₋₈alkyl)₂; or R₄ and R₅ together are a saturated or aromatic ring composed of 5 to 10 atoms including the phosphorus atom,

- 23 -

C_a, C_b are each a part of an aromatic, optionally substituted (hetero)aryl having at least 6 π -electrons,

R₆ is a hydrogen atom, a linear, branched or cyclic C₁₋₁₀alkyl or C₂₋₁₀alkenyl group, optionally substituted, an aromatic ring, optionally substituted, a -OR₆ or -NR₆R₆⁻ radical, where R₆ and R₆⁻ are as defined for R₆,

R₇ is a hydrogen atom, a linear, branched or cyclic C₁₋₁₀alkyl or C₂₋₁₀alkenyl group, or an R₇CO or R₇SO₂ radical where R₇ is a C₁₋₈alkyl or aryl group,
or

R₆ and R₇ together are an unsaturated (hetero)cycle composed of 5 to 10, optionally substituted ring atoms, including the carbon and the nitrogen atom to which R₆ and R₇ are bonded, and optionally including further heteroatoms.

2. Process according to Claim 1, characterized in that X, Y in the formula (I) are each independently a hydrogen atom or a halogen atom.

3. Process according to Claim 2, characterized in that X, Y in the formula (I) are each a halogen atom, in particular chlorine.

4. Process according to one of Claims 1 to 3, characterized in that R₁, R₂, R₃ in the formula (I) are each independently a methyl, ethyl, propyl, i-propyl, n-butyl, i-butyl, sec-butyl, tert-butyl, cyclopentyl, cyclohexyl, phenyl, o- or p-tolyl, p-isopropylphenyl or mesityl group.


5. Process according to one of Claims 1 to 4, characterized in that R₄, R₅ in the formula (I) are each independently a radical selected from methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, cyclohexyl, phenyl, o- or p-tolyl, mesityl, α - or β -naphthyl.

6. Process according to one of Claims 1 to 5, characterized in that C_a, C_b in the formula (II) are part of a pure 6 π -electron system in the form of optionally substituted benzene or in the form of an optionally substituted cyclopentadienide ion as a ligand of a metallocene.

7. Process according to one of Claims 1 to 6, characterized in that R₆ and R₇ in the formula (II) together are an unsaturated heterocycle composed of 5 to 10, optionally substituted ring atoms, including the carbon and the nitrogen atom to which R₆ and R₇ are bonded, and optionally including further heteroatoms.

- 24 -

8. Process according to one of Claims 1 to 5, characterized in that the ligand of the formula (II) is a ligand of the general formula (IIIb)



where

$n = 1$ or 2 , preferably 1 ,

$M = \text{Fe, Ru, Os}$, preferably Fe ,

$X = \text{O, S or N}$, preferably O ,

R_4, R_5 are each radicals corresponding to the definition given under formula (II),

R_{11} is a C_{2-8} alkoxyalkyl, C_{7-19} aralkyl, C_{3-18} heteroaryl, C_{4-19} heteroaralkyl,

$(\text{C}_{1-8}\text{alkyl})_{1-3}\text{-C}_{6-18}(\text{hetero})\text{aryl}$, $(\text{C}_{1-8}\text{alkyl})_{1-3}\text{-C}_{6-18}\text{cycloalkyl}$, $\text{C}_{3-8}\text{cycloalkyl}$,

$\text{C}_{3-8}\text{cycloalkyl-C}_{1-8}\text{alkyl}$ radical, or preferably $\text{C}_{1-8}\text{alkyl}$, $\text{C}_{6-18}\text{aryl}$ radical, in particular *i*-propyl, and the radicals mentioned may be substituted by one or more heteroatoms such as $\text{Hal, Si, N, O, P, S}$, or the radicals may have one or more heteroatoms such as Si, N, O, P, S in their carbon framework,


$R_{8,9,10}$ are each independently a $\text{C}_{1-8}\text{alkyl}$, $\text{C}_{2-8}\text{alkoxyalkyl}$, $\text{C}_{6-18}\text{aryl}$, $\text{C}_{7-19}\text{aralkyl}$,

$\text{C}_{3-18}\text{heteroaryl}$, $\text{C}_{4-19}\text{heteroaralkyl}$, $(\text{C}_{1-8}\text{alkyl})_{1-3}\text{-C}_{6-18}(\text{hetero})\text{aryl}$, $\text{C}_{3-8}\text{cycloalkyl}$,


$(\text{C}_{1-8}\text{alkyl})_{1-3}\text{-C}_{6-18}\text{cycloalkyl}$, $\text{C}_{3-8}\text{cycloalkyl-C}_{1-8}\text{alkyl}$ radical, or preferably H , and the radicals mentioned may be substituted by one or more heteroatoms such as $\text{Hal, Si, N, O, P, S}$, or the radicals may have one or more heteroatoms such as Si, N, O, P, S in their carbon framework.

- 25 -

9. Process according to Claim 8, characterized in that the ligand of the formula (IIIb) is selected from the ligands A to G:



10. Process according to one of Claims 1 to 5, characterized in that the ligand of the formula (II) is a ligand of the general formula (IV)



where

$n = 1$ or 2 , preferably 1 ,

$X = O, S$ or N , preferably O ,

R_4, R_5 are each radicals corresponding to the definition given under formula (II),

R_{11} is a C_{2-8} alkoxyalkyl, C_{7-19} aralkyl, C_{3-18} heteroaryl, C_{4-19} heteroaralkyl,


$(C_{1-8}alkyl)_{1-3}$ - C_{6-18} (hetero)aryl, $(C_{1-8}alkyl)_{1-3}$ - C_{6-18} cycloalkyl, C_{3-8} cycloalkyl,

- 26 -


C₃₋₈cycloalkyl-C₁₋₈alkyl radical, or preferably C₁₋₈alkyl, C₆₋₁₈aryl radical, in particular i-propyl, and the radicals mentioned may be substituted by one or more heteroatoms such as Hal, Si, N, O, P, S, or the radicals may have one or more heteroatoms such as Si, N, O, P, S in their carbon framework,

R₁₂, R₁₃ are each independently a C₁₋₈alkyl, C₁₋₄alkoxy radical, or preferably H, or are together a fused cycloalkyl or aryl ring.

12. Process according to Claim 11, characterized in that the ligand of the formula (IV) corresponds to the formula J:






13. Process according to one of Claims 1 to 5, characterized in that the ligand of the formula (II) is a ligand of the general formula (V)



where

n, X, R₄, R₅ and R₁₁ are each as defined in Claim 10 for formula (IV), and R₁₄ and R₁₅ together are a 6 π - or 10 π -electron heteroaromatic system, optionally substituted by linear or branched C₁₋₈alkyl radicals, and possible heteroatoms are N, O, or S.


14. Process according to Claim 13, characterized in that the ligand of the formula (V) corresponds to one of the formulae H, I and K:



- 27 -

15. Process according to Claim 1, characterized in that the substrate to be hydrogenated is a prochiral imine or ketone.


16. Process according to Claim 15, characterized in that the substrate to be hydrogenated is a prochiral ketone of the general formula (S)




where R_a and R_b are each independently a hydrogen atom, a cyclic, linear or branched C_{1-8} alkyl or C_{2-8} alkenyl group, or an monocyclic or polycyclic aryl or heteroaryl group, optionally substituted by linear or branched C_{1-8} alkyl, C_{1-8} alkoxy groups, or halogen atoms.

17. Process according to Claim 16, characterized in that the substrate to be hydrogenated is a prochiral monocyclic or polycyclic aryl ketone or heteroaryl ketone, optionally substituted by linear or branched C_{1-8} alkyl, C_{1-8} alkoxy groups, or halogen atoms.


18. Process according to Claim 17, characterized in that the substrate to be hydrogenated is selected from one of ketones 1 to 7:




1




2




3




4



5



6



7

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/50902

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07B53/00 C07B41/02 C07B43/04 C07D333/16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07B C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ARIKAWA Y ET AL: "Ruthenium(II)-catalyzed asymmetric transfer hydrogenation of ketones using chiral oxazolinylferrocenylphosphines and one of their Ru(II) complex" JOURNAL OF ORGANOMETALLIC CHEMISTRY, ELSEVIER-SEQUOIA S.A. LAUSANNE, CH, vol. 572, no. 2, 15. January 1999 (1999-01-15), pages 163-168, XP004152862 ISSN: 0022-328X cited in the application the whole document ----- -/--	1-18



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

Date of the actual completion of the international search

30 March 2004

Date of mailing of the international search report

08/04/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Diederer, J

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/50902

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	YOSHIAKI NISHIBAYASHI ET AL.: "Extremely high enantioselective redox reaction of ketones and alcohols catalyzed by RuCl ₂ (PPh ₃)(oxazolinylferrocenylphosphine)" ORGANOMETALLICS, vol. 18, 1999, pages 2291-93, XP002275450 cited in the application the whole document	1-18
A	WO 02/22526 A (ABDUR RASHID KAMALUDDIN ; MORRIS ROBERT HAROLD (CA); CHALLAND RENE (CH) 21 March 2002 (2002-03-21) cited in the application the whole document	1
A	KAMALUDDIN ABDUR-RASHID: "Ruthenium dihydride RuH ₂ (PPh ₃) ₂ ((R,R)-cyclohexyldiamine): active catalyst and catalyst precursor for the hydrogenation of ketones and imines" ORGANOMETALLICS, vol. 19, 2000, pages 2655-2657, XP002275451 cited in the application the whole document	1
A	WO 02/04466 A (BERG VAN DEN MICHEL ; FERINGA BEN (NL); DSM NV (NL); MINNAARD ADRIAAN) 17 January 2002 (2002-01-17) claims examples	1

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/50902

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0222526	A	21-03-2002	AU 8002801 A	26-03-2002
			CA 2422029 A1	21-03-2002
			EP 1366004 A2	03-12-2003
			WO 0222526 A2	21-03-2002
WO 0204466	A	17-01-2002	NL 1015655 C2	08-01-2002
			AU 7114501 A	21-01-2002
			CA 2414202 A1	17-01-2002
			CN 1440416 T	03-09-2003
			CZ 20030041 A3	16-04-2003
			EP 1325013 A2	09-07-2003
			JP 2004502543 T	29-01-2004
			WO 0204466 A2	17-01-2002
			US 2003199713 A1	23-10-2003